TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting The second-line setting for HER2-mutated NSCLC is shifting with TKIs looking to demonstrate efficacy and T-DXd under examination in the frontline now.

TKIs Look to Solidify a Role Alongside T-DXd in the Second-Line HER2-Mutant NSCLC Setting @ascocancer.bsky.social @iaslc.bsky.social #ASCO24 #ESMOASIA24 #WCLC24 #lcsm #oncology
www.onclive.com/view/tkis-lo...

No 10: ACANSULIMAB (BNT311/GEN1046)

Acasunlimab is a bi-specific Ab targeting both PD-L1 and 4-1BB (or CD137), a member of the TNF superfamily. CD137 stimulation led to >50% DCR in ph1 as mono- or in combo with pembro, as presented in #WCLC24
@LuisPaz_Ares @BioNTech_Group